BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 30953211)

  • 1. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
    Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of
    Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The
    Mansjö M; Karlsson Lindsjö O; Grönfors Seeth C; Groenheit R; Werngren J
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0102622. PubMed ID: 36409105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
    Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
    Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
    Gómez-González PJ; Perdigao J; Gomes P; Puyen ZM; Santos-Lazaro D; Napier G; Hibberd ML; Viveiros M; Portugal I; Campino S; Phelan JE; Clark TG
    Sci Rep; 2021 Sep; 11(1):19431. PubMed ID: 34593898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
    Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
    Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil.
    Matsui T; Pinhata JMW; Rabello MCDS; Brandão AP; Ferrazoli L; Leão SC; Viana-Niero C; Oliveira RS
    Mem Inst Oswaldo Cruz; 2020; 115():e200055. PubMed ID: 32401997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining MDR-TB: Comparison of Mycobacterium tuberculosis clinical isolates from Russia and Taiwan.
    Jou R; Lee WT; Kulagina EV; Weng JY; Isakova AI; Lin WH; Antonova OV; Wu MH; Arslanbaeva LR; Tasi HY; Nosova EY; Zimenkov DV
    Infect Genet Evol; 2019 Aug; 72():141-146. PubMed ID: 30593924
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Leechawengwongs M; Prammananan T; Jaitrong S; Billamas P; Makhao N; Thamnongdee N; Thanormchat A; Phurattanakornkul A; Rattanarangsee S; Ratanajaraya C; Disratthakit A; Chaiprasert A
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycobacterial interspersed repetitive unit typing and mutational profile for multidrug-resistant and extensively drug-resistant tuberculosis surveillance in Portugal: a 3-year period overview.
    Silva C; Perdigão J; Jordão L; Portugal I
    Int J Antimicrob Agents; 2014 Dec; 44(6):546-51. PubMed ID: 25270633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant
    Ghajavand H; Kargarpour Kamakoli M; Khanipour S; Pourazar Dizaji S; Masoumi M; Rahimi Jamnani F; Fateh A; Yaseri M; Siadat SD; Vaziri F
    Antimicrob Resist Infect Control; 2019; 8():70. PubMed ID: 31073401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.
    Ei PW; Aung WW; Nyunt WW; Swe TL; Htwe MM; Win SM; Aung ST; Chang CL; Lee HY; Lee JS
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):47-53. PubMed ID: 29297425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
    Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
    Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.
    Hoffmann H; Kohl TA; Hofmann-Thiel S; Merker M; Beckert P; Jaton K; Nedialkova L; Sahalchyk E; Rothe T; Keller PM; Niemann S
    Am J Respir Crit Care Med; 2016 Feb; 193(3):337-40. PubMed ID: 26829425
    [No Abstract]   [Full Text] [Related]  

  • 20. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
    Stinson K; Kurepina N; Venter A; Fujiwara M; Kawasaki M; Timm J; Shashkina E; Kreiswirth BN; Liu Y; Matsumoto M; Geiter L
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3316-22. PubMed ID: 26976868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.